Brief: Hutchmed (China) Gets NMPA Conditional Approval For Tazverik® (Tazemetostat)

HUTCHMED (China)

21/03/2025 12:00

March 21 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

NMPA CONDITIONAL APPROVAL FOR TAZVERIK® (TAZEMETOSTAT) FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))